本文介绍了2012年研发支出在世界排名前10位的制药公司，将汇率因素计算在内，2012年这些公司的总研发费用达703.7亿美元，同比前一年的703.8亿美元有稍有下降。但是大多数公司，比如诺华，默克，强生，葛兰素史克，赛诺菲，礼来，阿斯利康和雅培的研发支出基本持平，只有辉瑞公司的支出大幅下降，而罗氏的一部分支出用在了大规模一次性重组上。AbbVie公司现在已经从雅培公司中拆分出来，形成了一个独立的生物制药企业。“,” The top-line R&D spending for the top 10 pharma companies was introduced. The gross research budgets for these companies hit $70.37 billion last year, down ever so slightly from $70.38 billion the year before, when viewed at constant exchange rates. But while most companies carefully stayed on an unchanged budget track--Novartis, Merck, J&J, GlaxoSmithKline, Sanofi, Eli Lilly, AstraZeneca and Abbott--Pfizer registered the big drop in spending that had long ago been forecast. Roche, meanwhile, saw its numbers jump in the face of some big, one-time restructuring costs. And Abbott is making an appearance for the last time as AbbVie has now spun out to forge its own unique path in the biopharma business.